Published in Cancer Res on July 01, 2007
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Targeting the RB-pathway in cancer therapy. Clin Cancer Res (2010) 1.54
The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res (2008) 1.21
RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget (2015) 1.20
Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res (2012) 1.20
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res (2015) 1.13
The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer (2015) 1.09
Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression. Oncogene (2008) 1.08
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Two different specific JNK activators are required to trigger apoptosis or compensatory proliferation in response to Rbf1 in Drosophila. Cell Cycle (2016) 1.00
Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep (2012) 0.99
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Mol Cancer (2010) 0.96
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol (2011) 0.94
RB1: a prototype tumor suppressor and an enigma. Genes Dev (2016) 0.93
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Mutating RBF can enhance its pro-apoptotic activity and uncovers a new role in tissue homeostasis. PLoS One (2014) 0.90
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology (2010) 0.90
RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One (2013) 0.87
Stress and IGF-I differentially control cell fate through mammalian target of rapamycin (mTOR) and retinoblastoma protein (pRB). J Biol Chem (2008) 0.84
AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res (2015) 0.84
The pro-apoptotic activity of Drosophila Rbf1 involves dE2F2-dependent downregulation of diap1 and buffy mRNA. Cell Death Dis (2014) 0.82
Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model. PLoS One (2010) 0.81
Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res (2015) 0.80
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget (2015) 0.79
The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. Clin Cancer Res (2014) 0.78
pRb controls estrogen receptor alpha protein stability and activity. Oncotarget (2013) 0.76
Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma. BMC Cancer (2017) 0.75
Adjusting for misclassification in a stratified biomarker clinical trial. Stat Med (2014) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature (2003) 6.01
The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer (2002) 4.48
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
RB and cell cycle progression. Oncogene (2006) 3.77
Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell (2006) 3.12
Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci (2004) 2.89
Current indications for chemotherapy in prostate cancer patients. Eur Urol (2006) 2.68
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res (2006) 2.46
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem (2002) 2.28
Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res (2006) 2.23
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 2.16
RB-dependent S-phase response to DNA damage. Mol Cell Biol (2000) 2.08
Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate (2004) 1.96
Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene (1998) 1.82
Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A (1990) 1.82
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem (1998) 1.79
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A (2006) 1.67
Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc Natl Acad Sci U S A (2000) 1.59
Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res (2002) 1.55
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene (2002) 1.52
Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res (2006) 1.36
Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res (2000) 1.35
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
Conditional deletion of Rb causes early stage prostate cancer. Cancer Res (2004) 1.23
Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate (2001) 1.18
The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J Biol Chem (2000) 1.14
Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. J Biol Chem (2004) 1.11
Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res (1997) 1.11
Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res (2005) 1.10
p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int J Oncol (1999) 1.07
FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest (2000) 1.03
Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett (2002) 0.99
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res (2006) 0.99
The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol (2006) 0.96
Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. Cell Growth Differ (2000) 0.93
Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma. Am J Clin Oncol (2004) 0.92
Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis. Breast Cancer Res Treat (2005) 0.91
Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate (1998) 0.88
Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer (1996) 0.88
pRb-Independent growth arrest and transcriptional regulation of E2F target genes. Neoplasia (2005) 0.82
A critical review of maximal androgen blockade for advanced prostate cancer. Rev Urol (2004) 0.78
Bicalutamide dosages used in the treatment of prostate cancer. Prostate (1999) 0.78
pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res (2004) 0.78
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol (2007) 4.04
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem (2003) 2.12
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (2010) 1.96
Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle (2011) 1.92
Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol (2009) 1.87
An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol (2007) 1.83
Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene (2002) 1.81
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther (2008) 1.79
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res (2012) 1.78
SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res (2005) 1.68
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J Biol Chem (2004) 1.64
The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther (2002) 1.63
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest (2012) 1.62
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (2011) 1.55
Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res (2002) 1.55
Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res (2005) 1.54
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (2012) 1.54
Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene (2002) 1.52
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A (2006) 1.52
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res (2002) 1.51
E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res (2004) 1.50
RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle (2007) 1.45
Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res (2010) 1.45
SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol Biol Cell (2009) 1.41
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood) (2006) 1.38
The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res (2009) 1.37
Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J Biol Chem (2001) 1.37
RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology (2007) 1.36
FOXA1: master of steroid receptor function in cancer. EMBO J (2011) 1.36
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer (2011) 1.35
Dynamic targeting of the replication machinery to sites of DNA damage. J Cell Biol (2004) 1.35
RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res (2004) 1.33
The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression. J Biol Chem (2004) 1.33
BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol (2005) 1.32
Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem (2001) 1.32
Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life. Endocrinology (2011) 1.31
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res (2008) 1.30
Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J Biol Chem (2005) 1.28
Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology (2010) 1.26
Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res (2008) 1.26
Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem (2003) 1.23
The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology (2002) 1.22
The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood (2007) 1.22
The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Mol Biol Cell (2008) 1.21
The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res (2008) 1.21
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle (2012) 1.20
LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology (2005) 1.19
Regulation of RB transcription in vivo by RB family members. Mol Cell Biol (2010) 1.18
Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer (2006) 1.17
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res (2007) 1.16
RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell (2011) 1.16
Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem (2002) 1.16
A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene (2005) 1.12
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol (2011) 1.12
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther (2006) 1.11
Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. J Biol Chem (2004) 1.11
RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors. J Biol Chem (2007) 1.10
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
Retinoblastoma/p107/p130 pocket proteins: protein dynamics and interactions with target gene promoters. J Biol Chem (2009) 1.07
Specificity of cyclin D1 for androgen receptor regulation. Cancer Res (2003) 1.06
Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol Cell Biol (2009) 1.06
Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner. Blood (2009) 1.05
Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene (2004) 1.05
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res (2010) 1.04
Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol (2003) 1.04
Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem (2012) 1.03
Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res (2005) 1.03
Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci (2010) 1.03
RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2012) 1.03
2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol Pharmacol (2004) 1.01